{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:15:48Z","timestamp":1789143348543,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,16]]},"DOI":"10.7759\/cureus.75806","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T17:01:33Z","timestamp":1734368493000},"source":"Crossref","is-referenced-by-count":1,"title":["Optimizing Propranolol Therapy for Infantile Hemangiomas: The Role of the Multidisciplinary Team"],"prefix":"10.7759","author":[{"given":"Mayu","family":"Yasuda-Koiwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Mukoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Moriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Isojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01568.x","article-title":"A prospective study of infantile hemangiomas with a focus on incidence and risk factors","volume":"28","author":"Dickison P","year":"2011","unstructured":"Dickison P, Christou E, Wargon O. A prospective study of infantile hemangiomas with a focus on incidence and risk factors. Pediatr Dermatol. 2011, 28:663-9. 10.1111\/j.1525-1470.2011.01568.x","journal-title":"Pediatr Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3475","article-title":"Clinical practice guideline for the management of infantile hemangiomas","volume":"143","author":"Krowchuk DP","year":"2019","unstructured":"Krowchuk DP, Frieden IJ, Mancini AJ, et al.. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019, 143:e20183475. 10.1542\/peds.2018-3475","journal-title":"Pediatrics"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2016.02.038","article-title":"The treatment of problematic hemangiomas in children with propranolol and 940nm diode laser","volume":"51","author":"Dementieva N","year":"2016","unstructured":"Dementieva N, Jones S. The treatment of problematic hemangiomas in children with propranolol and 940nm diode laser. J Pediatr Surg. 2016, 51:863-8. 10.1016\/j.jpedsurg.2016.02.038","journal-title":"J Pediatr Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-1128","article-title":"Infantile hemangiomas: an update on pathogenesis and therapy","volume":"131","author":"Chen TS","year":"2013","unstructured":"Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics. 2013, 131:99-108. 10.1542\/peds.2012-1128","journal-title":"Pediatrics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.08.019","article-title":"Infantile hemangioma. Part 1: epidemiology, pathogenesis, clinical presentation and assessment","volume":"85","author":"Rodr\u00edguez Bandera AI","year":"2021","unstructured":"Rodr\u00edguez Bandera AI, Sebaratnam DF, Wargon O, Wong LC. Infantile hemangioma. Part 1: epidemiology, pathogenesis, clinical presentation and assessment. J Am Acad Dermatol. 2021, 85:1379-92. 10.1016\/j.jaad.2021.08.019","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1993.tb00393.x","article-title":"The current management of vascular birthmarks","volume":"10","author":"Enjolras O","year":"1993","unstructured":"Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol. 1993, 10:311-3. 10.1111\/j.1525-1470.1993.tb00393.x","journal-title":"Pediatr Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1986.tb00505.x","article-title":"Statistical survey of skin changes in Japanese neonates","volume":"3","author":"Hidano A","year":"1986","unstructured":"Hidano A, Purwoko R, Jitsukawa K. Statistical survey of skin changes in Japanese neonates. Pediatr Dermatol. 1986, 3:140-4. 10.1111\/j.1525-1470.1986.tb00505.x","journal-title":"Pediatr Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-019-00327-2","article-title":"Risk factors for infantile hemangioma: a meta-analysis","volume":"16","author":"Ding Y","year":"2020","unstructured":"Ding Y, Zhang JZ, Yu SR, Xiang F, Kang XJ. Risk factors for infantile hemangioma: a meta-analysis. World J Pediatr. 2020, 16:377-84. 10.1007\/s12519-019-00327-2","journal-title":"World J Pediatr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","author":"L\u00e9aut\u00e9-Labr\u00e8ze C","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J, et al.. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015, 372:735-46. 10.1056\/NEJMoa1404710","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ped.13318","article-title":"Efficacy and safety of oral propranolol for infantile hemangioma in Japan","volume":"59","author":"Kaneko T","year":"2017","unstructured":"Kaneko T, Sasaki S, Baba N, et al.. Efficacy and safety of oral propranolol for infantile hemangioma in Japan. Pediatr Int. 2017, 59:869-77. 10.1111\/ped.13318","journal-title":"Pediatr Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2022.01086","article-title":"A study of 95 infantile hemangiomas treated with propranolol: a potentially efficacious combination with laser therapy","volume":"17","author":"Yamada-Kanazawa S","year":"2023","unstructured":"Yamada-Kanazawa S, Shimada S, Nakayama W, et al.. A study of 95 infantile hemangiomas treated with propranolol: a potentially efficacious combination with laser therapy. Drug Discov Ther. 2023, 17:70-2. 10.5582\/ddt.2022.01086","journal-title":"Drug Discov Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14077","article-title":"Japanese clinical practice guidelines for vascular anomalies 2017","volume":"62","author":"Mimura H","year":"2020","unstructured":"Mimura H, Akita S, Fujino A, et al.. Japanese clinical practice guidelines for vascular anomalies 2017. Pediatr Int. 2020, 62:257-304. 10.1111\/ped.14077","journal-title":"Pediatr Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-04827-2","article-title":"Management of infantile hemangiomas-experience of a tertiary hospital","volume":"182","author":"Gomes R","year":"2023","unstructured":"Gomes R, Salazar L, Fraga C, et al.. Management of infantile hemangiomas-experience of a tertiary hospital. Eur J Pediatr. 2023, 182:1611-8. 10.1007\/s00431-023-04827-2","journal-title":"Eur J Pediatr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-1691","article-title":"Initiation and use of propranolol for infantile hemangioma: report of a consensus conference","volume":"131","author":"Drolet BA","year":"2013","unstructured":"Drolet BA, Frommelt PC, Chamlin SL, et al.. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013, 131:128-40. 10.1542\/peds.2012-1691","journal-title":"Pediatrics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13455","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes","volume":"23","author":"de Bock M","year":"2022","unstructured":"de Bock M, Codner E, Craig ME, et al.. ISPAD Clinical Practice Consensus Guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes. 2022, 23:1270-6. 10.1111\/pedi.13455","journal-title":"Pediatr Diabetes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/srep43292","article-title":"When to stop propranolol for infantile hemangioma","volume":"7","author":"Chang L","year":"2017","unstructured":"Chang L, Gu Y, Yu Z, et al.. When to stop propranolol for infantile hemangioma. Sci Rep. 2017, 7:43292. 10.1038\/srep43292","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ped.13109","article-title":"Low-dose propranolol for infantile hemangioma of the head and neck: analysis of 23 consecutive patients","volume":"59","author":"Ren W","year":"2017","unstructured":"Ren W, Li S, Gao L, et al.. Low-dose propranolol for infantile hemangioma of the head and neck: analysis of 23 consecutive patients. Pediatr Int. 2017, 59:213-7. 10.1111\/ped.13109","journal-title":"Pediatr Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2019.32.155.16760","article-title":"Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study","volume":"32","author":"Prasad A","year":"2019","unstructured":"Prasad A, Sinha AK, Kumar B, Prasad A, Kumari M. Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study. Pan Afr Med J. 2019, 32:155. 10.11604\/pamj.2019.32.155.16760","journal-title":"Pan Afr Med J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0353","article-title":"Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review","volume":"138","author":"L\u00e9aute-Labr\u00e8ze C","year":"2016","unstructured":"L\u00e9aute-Labr\u00e8ze C, Boccara O, Degrugillier-Chopinet C, et al.. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016, 138:e20160353. 10.1542\/peds.2016-0353","journal-title":"Pediatrics"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ped.15278","article-title":"Severe hypoglycemia in propranolol treatment for infantile hemangiomas","volume":"64","author":"Morimoto A","year":"2022","unstructured":"Morimoto A, Ozeki M, Sasaki S, Baba N, Kuwano Y, Kaneko T. Severe hypoglycemia in propranolol treatment for infantile hemangiomas. Pediatr Int. 2022, 64:e15278. 10.1111\/ped.15278","journal-title":"Pediatr Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-0413","article-title":"Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment","volume":"118","author":"Haggstrom AN","year":"2006","unstructured":"Haggstrom AN, Drolet BA, Baselga E, et al.. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006, 118:882-7. 10.1542\/peds.2006-0413","journal-title":"Pediatrics"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14517","article-title":"Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment","volume":"45","author":"Kagami S","year":"2018","unstructured":"Kagami S, Kaneko M, Kishi A, Katori T. Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. J Dermatol. 2018, 45:1109-12. 10.1111\/1346-8138.14517","journal-title":"J Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12158","article-title":"Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser","volume":"39","author":"Reddy KK","year":"2013","unstructured":"Reddy KK, Blei F, Brauer JA, et al.. Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser. Dermatol Surg. 2013, 39:923-33. 10.1111\/dsu.12158","journal-title":"Dermatol Surg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9493","article-title":"Short-term curative effect and safety of propranolol combined with laser in the treatment of infantile hemangiomas","volume":"16","author":"Sun X","year":"2018","unstructured":"Sun X, Liu X, Lu N, Yao S, Xu X, Niu L. Short-term curative effect and safety of propranolol combined with laser in the treatment of infantile hemangiomas. Oncol Lett. 2018, 16:6561-5. 10.3892\/ol.2018.9493","journal-title":"Oncol Lett"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/319534-optimizing-propranolol-therapy-for-infantile-hemangiomas-the-role-of-the-multidisciplinary-team","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T17:01:34Z","timestamp":1734368494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/319534-optimizing-propranolol-therapy-for-infantile-hemangiomas-the-role-of-the-multidisciplinary-team"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.75806","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}